Go to main contentGo to footer

Ketamine Clinic

Due to their high efficacy toward the management of Treatment-Resistant Depression, Ketamine and Esketamine are considered a lifesaver for people suffering from this condition. These are drugs that can achieve with great speed a significant reduction in symptoms of depression and suicidal ideation.

Ketamine, given intravenously, might be the most important breakthrough in antidepressant treatment in decades.

Dr. Thomas Insel
Former Director of NIMH, 2014.

Ketamine and Esketamine for Treatment-Resistant Depression

Ketamine used for infusion therapy is composed of K-ketamine and S-ketamine, a widely-used medicine serving as an anesthetic. Esketamine, the S-ketamine, is given intranasally.

Administered with a low dose, they work on the neurotransmitters in the brain differently from traditional antidepressants like SSRIs. They are more successfully fast-acting in reducing the symptoms of depression and suicidal ideation. Some medical professionals regard them as lifesavers for Treatment-Resistant patients with Depression.

Esketamine had the FDA (Food and Drug Administration) approval in 2019 to address Treatment-Resistant Depression.

There exists no medicine that is “merely” good or bad: drugs are bad when they are used incorrectly.

Both Ketamine and Esketamine are hallucinogenic, and their misuse can cause medical peril. A careful examination of the individual case remains obligatory for choosing the right candidate and protocol. The administration of Ketamine and Esketamine should occur in controlled settings with close, long-term monitoring.